Trials / Completed
CompletedNCT04468607
A Study of BLYG8824A in Participants With Locally Advanced or Metastatic Colorectal Cancer
A Phase I, Open-Label, Dose-Escalation Study Of The Safety And Pharmacokinetics Of BLYG8824A Administered Intravenously In Patients With Locally Advanced Or Metastatic Colorectal Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 46 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety, tolerability, and pharmacokinetics of BLYG8824A and will make a preliminary assessment of the anti-tumor activity of BLYG8824A in patients with locally advanced or metastatic colorectal cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BLYG8824A | BLYG8824A will be administered at a flat dose independent of body weight. |
Timeline
- Start date
- 2020-08-31
- Primary completion
- 2024-10-16
- Completion
- 2024-10-16
- First posted
- 2020-07-13
- Last updated
- 2025-04-25
Locations
6 sites across 3 countries: United States, Australia, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04468607. Inclusion in this directory is not an endorsement.